LAX.SH
MANKIND PHARMA LIMITED·PHARMACEUTICALS 66.37SEXUAL WELLNESS 61.33·Pharmaceuticals & Biotechnology Companies
Price
2,275.6
-0.44%52W Range
Market Cap
₹93,992.54 Cr
Traded: ₹147.05 Cr (0.16%) 0.0x
Free Float: ₹2,378.01 Cr (6.18% of FF traded)
Volume · 60D trend
6.5 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +18.0% | +18.0% | -- | +14.0% | Stable |
| ROE | -- | +17.0% | +16.0% | -- | -- | Decelerating |
| Return | -- | -- | +14.0% | +0.0% | -- | Decelerating |
| Profit | -- | +11.0% | +17.0% | -- | +13.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,031 | 3,443 | 3,567 | 3,697 | 3,570 | 3,079 | 3,199 | 3,061 | 2,868 | 2,422 | 2,607 | 2,708 | 2,579 | 2,053 | 2,091 | 2,426 |
| Expenses | 2,974 | 2,513 | 2,648 | 2,776 | 2,724 | 2,396 | 2,383 | 2,214 | 2,196 | 1,836 | 2,000 | 2,025 | 1,924 | 1,636 | 1,654 | 1,835 |
| Operating Profit | 1,056 | 930 | 919 | 921 | 847 | 683 | 816 | 847 | 672 | 586 | 606 | 683 | 655 | 417 | 437 | 591 |
| Other Income | 49 | 94 | -31 | 94 | 83 | 249 | 87 | 109 | 108 | 94 | 75 | 63 | 63 | 50 | 40 | 31 |
| Interest | 110 | 142 | 157 | 170 | 171 | 191 | 221 | 7 | 11 | 9 | 9 | 9 | 6 | 5 | 13 | 10 |
| Depreciation | 226 | 223 | 223 | 222 | 219 | 231 | 187 | 100 | 103 | 100 | 110 | 96 | 87 | 85 | 85 | 79 |
| Profit Before Tax | 769 | 659 | 509 | 624 | 540 | 511 | 495 | 849 | 666 | 572 | 562 | 641 | 624 | 377 | 379 | 533 |
| Tax % | 25.0% | 15.0% | 19.0% | 17.0% | 18.0% | 17.0% | 22.0% | 22.0% | 18.0% | 17.0% | 18.0% | 20.0% | 21.0% | 22.0% | 22.0% | 21.0% |
| Net Profit | 574 | 559 | 414 | 520 | 445 | 425 | 385 | 659 | 543 | 477 | 460 | 511 | 494 | 294 | 296 | 423 |
| Exceptional Items | -- | -23 | -107 | 0 | 0 | -4 | 7 | -2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 13.8 | 13.4 | 9.9 | 12.4 | 10.6 | 10.2 | 9.2 | 16.3 | 13.4 | 11.8 | 11.3 | 12.5 | 12.2 | 7.1 | 7.1 | 10.5 |
| Sales Growth (YoY) | 12.9% | 11.8% | 11.5% | 20.8% | 24.5% | 27.1% | 22.7% | 13.0% | 11.2% | 18.0% | 24.7% | 11.6% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 17.1% | -3.5% | -3.5% | 3.6% | 15.9% | -3.8% | 4.5% | 6.7% | 18.4% | -7.1% | -3.7% | 5.0% | 25.6% | -1.8% | -13.8% | -- |
| OP Growth (YoY) | 24.7% | 36.2% | 12.6% | 8.7% | 26.0% | 16.6% | 34.7% | 24.0% | 2.6% | 40.5% | 38.7% | 15.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | 13.5% | 1.2% | -0.2% | 8.7% | 24.0% | -16.3% | -3.7% | 26.0% | 14.7% | -3.3% | -11.3% | 4.3% | 57.1% | -4.6% | -26.1% | -- |
| Profit Growth (YoY) | -- | 34.0% | 29.0% | -22.0% | -18.0% | -10.0% | -18.0% | 31.0% | 9.0% | 65.0% | 60.0% | 19.0% | 66.0% | 50.0% | -- | -- |
| EPS Growth (YoY) | 29.5% | 31.7% | 7.4% | -24.0% | -20.7% | -13.3% | -18.6% | 30.4% | 10.2% | 64.9% | 59.8% | 19.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 2.4% | 35.7% | -20.1% | 16.7% | 4.1% | 10.6% | -43.5% | 21.8% | 13.9% | 3.8% | -9.4% | 3.0% | 70.4% | 0.6% | -32.4% | -- |
| OP Margin | 26.2% | 27.0% | 25.8% | 24.9% | 23.7% | 22.2% | 25.5% | 27.7% | 23.4% | 24.2% | 23.3% | 25.2% | 25.4% | 20.3% | 20.9% | 24.4% |
| Net Margin | 14.2% | 16.2% | 11.6% | 14.1% | 12.5% | 13.8% | 12.0% | 21.5% | 18.9% | 19.7% | 17.6% | 18.9% | 19.1% | 14.3% | 14.2% | 17.4% |
| Material Cost % | -- | 27.8% | 27.4% | 28.7% | 29.5% | 28.4% | 29.1% | 28.5% | 28.2% | 30.3% | 31.8% | 30.5% | 31.8% | 32.8% | 32.5% | 33.2% |
| Employee Cost % | -- | 21.8% | 23.1% | 22.3% | 21.9% | 23.3% | 22.0% | 21.0% | 22.0% | 23.9% | 21.8% | 21.1% | 21.4% | 24.2% | 22.6% | 20.5% |
| P/S | 6.38 | 7.50 | 7.40 | 6.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 46.00 | 55.95 | 57.82 | 52.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.77 | 6.57 | 6.73 | 6.07 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Due to a technical issue, the meeting link provided in the earlier intimation regarding "Rescheduling of the Earnings Conference Call for Q2 & H1 FY27", uploaded today at 15:39:16 IST, ....
Please find attached Intimation regarding Schedule of Analyst/ Institutional Investors Meet
Please find attached intimation regarding rescheduling of Earnings Conference Call for Q2 & H1 FY27
Intimation regarding payment of interest and redemption of Non-Convertible Debentures ("NCD")
Please find attached intimation regarding ESG Rating
Please find attached press release titled "Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies".
Please find attached intimation regarding investment by the Company.
Please find attached outcome of Board Meeting held on October 15, 2026.
Please find attached intimation regarding Earnings Conference Call for Q2 & H1 FY27.
Please find attached certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended on September 30, 2026.
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve the unaudited standalon and ....
Please find attached Voting Results of Postal Ballot and Scrutinizer''s Report
Please find attached Voting Results of Postal Ballot and Scrutinizer''s Report
Please find attached intimation regarding ESG Rating
Please find attached intimation of participation in the Investor Conferences
Please find attached update on voluntary liquidation of Bharat Serums and Vaccines Limited, a wholly owned subsidiary company.
Please find attached intimation regarding allotment of 49,112 equity shares pursuant to ESOP Plan
Please find attached final update on sale of stake of Broadway Hospitality Services Private Limited, a wholly owned subsidiary company.
Please find attached intimation regarding completion of term of Independent Director
Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly ....
Please find attached outcome of the Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limited, a wholly ....
Please find attached intimation regarding ESG Rating
Please find attached press release dated August 20, 2026.
Please find attached Newspaper Advertisement of Notice of Postal Ballot
Please find attched postal ballot notice
Completion of realignment of Security Cover in respect of Non-Convertible Debentures.
Please find attached intimation regarding incorporation of a wholly owned subsidiary company in Netherlands
Please find attached intimation regarding participation in Investor Conferences
Please find attached outcome of board meeting
Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Director
Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Director
Please find attached Voting Results and Scrutinizer''s Report of 35th AGM
Please find attached proceedings of the 35th AGM of the Company
Please find attached un-audited financial results of the Company for the quarter ended on June 30, 2026
Please find attached certificate under Regulation 54 of the SEBI (LODR) Regulations, 2015
Intimation under Regulation 30 of the SEBI LODR
Please find attached intimation regarding investor conference call for Q1FY27.
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve the unaudited standalone and ....
Please find attached Outcome of Board Meeting held on July 11, 2026
Board of Directors of the Company in its meeting held today i.e., July 11, 2026 has approved the incorporation of a wholly owned subsidiary in Netherlands
Board of Directors of the Company has approved the divestment of 100 % stake held in Broadway Hospitality Services Private Limited, a wholly owned subsidiary company
Please find attached certificate under Regulation 74(5) of the SEBI DP Regulations, 2018 for the quarted ended on June 30, 2026
Please find attached newpaper advertisment regarding 35th Annual General Meeting of the Company
Please find attached notice of 35th Annual General Meeting of the Company
Please find attached BRSR Report for the financial year 2025-26
Please find attached Annual Report of the Company for the financial year 2025-26
Newspaper Advertisement regarding 35th Annual General Meeting of the Company.
Please find attached Intimation of the date of Thirty Fifth (35th) Annual General Meeting of the Company.
Please find attached intimation of closure of trading window
Please find attached intimation regarding participation in investor conference by management and officials of the Company
Credit Ratings
6Concalls
17Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Nov 2024
30 Nov 2024Sep 2024
30 Sept 2024Aug 2024
31 Aug 2024Aug 2024
31 Aug 2024Aug 2024
31 Aug 2024Jul 2024
31 Jul 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Jan 2024
31 Jan 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023Held by ETFs
33 ETFs hold MANKIND · sorted by weight
Held by Mutual Funds
150 schemes hold MANKIND · sorted by weight